Ignite Creation Date:
2025-12-24 @ 7:12 PM
Ignite Modification Date:
2026-02-03 @ 4:39 AM
Study NCT ID:
NCT02142803
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-13
First Post:
2014-05-16
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Adult Glioblastoma | View |
| None | Endometrial Clear Cell Adenocarcinoma | View |
| None | Endometrial Serous Adenocarcinoma | View |
| None | Ovarian Clear Cell Cystadenocarcinoma | View |
| None | Ovarian Endometrioid Adenocarcinoma | View |
| None | Ovarian Mucinous Cystadenocarcinoma | View |
| None | Ovarian Serous Cystadenocarcinoma | View |
| None | Recurrent Fallopian Tube Carcinoma | View |
| None | Recurrent Malignant Uterine Corpus Neoplasm | View |
| None | Recurrent Ovarian Carcinoma | View |
| None | Recurrent Primary Peritoneal Carcinoma | View |
| None | Solid Neoplasm | View |
| None | Stage IIIA Fallopian Tube Cancer AJCC v7 | View |
| None | Stage IIIA Ovarian Cancer AJCC v6 and v7 | View |
| None | Stage IIIA Primary Peritoneal Cancer AJCC v7 | View |
| None | Stage IIIB Fallopian Tube Cancer AJCC v7 | View |
| None | Stage IIIB Ovarian Cancer AJCC v6 and v7 | View |
| None | Stage IIIB Primary Peritoneal Cancer AJCC v7 | View |
| None | Stage IIIC Fallopian Tube Cancer AJCC v7 | View |
| None | Stage IIIC Ovarian Cancer AJCC v6 and v7 | View |
| None | Stage IIIC Primary Peritoneal Cancer AJCC v7 | View |
| None | Stage IV Fallopian Tube Cancer AJCC v6 and v7 | View |
| None | Stage IV Ovarian Cancer AJCC v6 and v7 | View |
| None | Stage IV Primary Peritoneal Cancer AJCC v7 | View |
Keywords: